Cassava Sciences Invited to Participate in B. Riley Securities’ Neuroscience Conference
April 27 2021 - 8:30AM
Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage
biotechnology company focused on Alzheimer’s disease, today
announced that it has been invited to participate in the B. Riley
Securities’ Neuroscience Conference, a virtual event taking place
on April 28-29, 2021. The B. Riley Securities' Neuroscience
Conference will cover key topics across neurodegeneration and
neuropsychiatry disease areas with leading companies in the field.
Remi Barbier, President & CEO, will
participate in a virtual Fireside Chat led by the research team at
B. Riley Securities on Wednesday, April 28, 2021 at 2:30 PM – 3:00
PM Eastern time. The link for this webcast is:
https://www.webcaster4.com/Webcast/Page/2433/41052. An archived
replay of the Fireside Chat will be available on Cassava Sciences’
website for approximately 90 days following the event.
About Cassava Sciences,
Inc.Cassava Sciences’ mission is to discover and develop
innovations for chronic, neurodegenerative conditions. Over the
past 10 years, Cassava Sciences has combined state-of-the-art
technology with new insights in neurobiology to develop novel
solutions for Alzheimer’s disease. For more information, please
visit: https://www.CassavaSciences.com.
For More Information Contact:
Eric Schoen, Chief Financial
Officereschoen@CassavaSciences.com(512) 501-2450
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Cassava Sciences (NASDAQ:SAVA)
Historical Stock Chart
From Sep 2023 to Sep 2024